Bio&Tech Smart Capital
VC Fund
Santiago De Compostela, Spain
Bio&Tech Smart Capital is a VC fund in Santiago De Compostela focused on Medical and Health Care. Bio&Tech Smart Capital is the alliance of researchers and entrepreneurs with Venture Capital management professionals to transfer scientific knowledge to society.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Bio&Tech Smart Capital invests in
Stages Bio&Tech Smart Capital invests in
Countries Bio&Tech Smart Capital invests in
Round sizes
Round size
- Venture - Series Unknown
- $330k–$7.1M
Investment Focus
Industry
- Medical 2 (33%)
- Health Care 2 (33%)
- Pharmaceutical 2 (33%)
- Information Technology 2 (33%)
- Genetics 1 (17%)
Stage
- Series A 2 (33%)
- Venture - Series Unknown 2 (33%)
- Seed 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Pharmacelera is a company that applies accurate Quantum-Mechanics (QM) algorithms, Machine Learning (ML) and High-Performance Computing (HPC) to mine an unexploited chemical space and propose molecular candidates that have higher chances to become a drug. The patented computational technology derives from more than 25 years of research at theUniversity of Barcelona and it has been validated in scientific peer-reviewed publications and benchmarking studies performed by our users and customers. | $7.1M / Venture - Series Unknown / Feb 18, 2026 | ||
| Oncostellae has been founded in 2013 by a group of researchers (chemists, biochemists and pharmacologists) who have a common track record in developing clinical drug candidates until phase II. Our objective is to discover and develop small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novelmodulators of validated cancer targets like e.g. nuclear receptors and kinases. The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company. | $329.9K / Venture - Series Unknown / Sep 17, 2025 | ||
| ADNTRO Genetics offers human genetics research, personalized nutrition plan, personal health, consulting and services | $1.1M / Seed / Oct 07, 2024 | ||
| Oncostellae has been founded in 2013 by a group of researchers (chemists, biochemists and pharmacologists) who have a common track record in developing clinical drug candidates until phase II. Our objective is to discover and develop small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novelmodulators of validated cancer targets like e.g. nuclear receptors and kinases. The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company. | Series A / Mar 18, 2024 | ||
| Zerintia HealthTech is specialized in Digital Health. We work to promote the use of technology in medicine in order to make it easier for doctors to diagnose, care and attend to their patients. | $1.1M / Series A / Jul 06, 2023 | ||
| Oncostellae has been founded in 2013 by a group of researchers (chemists, biochemists and pharmacologists) who have a common track record in developing clinical drug candidates until phase II. Our objective is to discover and develop small molecule drugs for the treatment of cancer by generating pharmaceutical research programs around novelmodulators of validated cancer targets like e.g. nuclear receptors and kinases. The company’s strategy includes running the discovery and development process with limited headcounts and focusing internal activities on project management, medicinal chemistry and in vitro pharmacology. The remaining activities of the R&D process like in vivo pharmacology, toxicology and clinical trials are subcontracted to qualified providers.The commercial goal is to license a clinical drug candidate including intellectual property and preclinical/clinical data package to a consolidated pharmaceutical or biotechnological company. | $3.2M / Venture - Series Unknown / Nov 03, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bio&Tech Smart Capital invest in?
Bio&Tech Smart Capital invests primarily in Medical, Health Care and Pharmaceutical startups, most often at Series A and Venture - Series Unknown stage. Most of the 6 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bio&Tech Smart Capital's check size?
Bio&Tech Smart Capital typically joins rounds of $330k–$7.1M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bio&Tech Smart Capital participates in.
When did Bio&Tech Smart Capital last invest?
The most recent investment recorded for Bio&Tech Smart Capital closed in Feb 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
